Design Therapeutics, Inc.
DSGN
$14.83
$0.443.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 6.59% | 16.43% | 33.32% | 33.92% | 23.69% |
| Gross Profit | -6.59% | -16.43% | -33.32% | -33.92% | -23.69% |
| SG&A Expenses | 4.06% | 11.63% | 12.78% | 14.35% | 5.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.92% | 15.14% | 27.39% | 28.26% | 18.21% |
| Operating Income | -5.92% | -15.14% | -27.39% | -28.26% | -18.21% |
| Income Before Tax | -11.51% | -24.05% | -40.74% | -41.16% | -25.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.51% | -24.05% | -40.74% | -41.16% | -25.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.51% | -24.05% | -40.74% | -41.16% | -25.65% |
| EBIT | -5.92% | -15.14% | -27.39% | -28.26% | -18.21% |
| EBITDA | -5.96% | -15.26% | -27.61% | -28.48% | -18.30% |
| EPS Basic | -5.51% | -20.35% | -39.07% | -40.21% | -24.56% |
| Normalized Basic EPS | -5.49% | -20.35% | -39.08% | -40.22% | -24.54% |
| EPS Diluted | -5.51% | -20.35% | -39.07% | -40.21% | -24.56% |
| Normalized Diluted EPS | -5.49% | -20.35% | -39.08% | -40.22% | -24.54% |
| Average Basic Shares Outstanding | 5.60% | 3.25% | 1.31% | 0.66% | 0.80% |
| Average Diluted Shares Outstanding | 5.60% | 3.25% | 1.31% | 0.66% | 0.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |